Directory › Recipharm

Recipharm — Bengaluru

Bengaluru, India · CDMO

This is a record of what regulators published, not a rating.

Site facts

Company
Recipharm
Name(s) in FDA data
Recipharm Pharmaservices Private Limited
FEI number(s)
3009150119 (present in FDA Data Dashboard records for this name and city)
Location (as in FDA data)
Bengaluru, India
Records matched
6 FDA inspections · 1 inspection with posted 483 citations
Most recent FDA inspection in dataset
22 Mar 2024 — NAI

Capabilities (from the company's website)

  • Oral solid dose
    …support full product lifecycle needs, including: Analytical services Technology transfer Oral solid dose manufacturing Semi solid manufacturing Liquid dosage manufacturing Quality, complian…
  • Oral liquids & semi-solids
    …pharm Bengaluru delivers flexible and reliable manufacturing across solid, semi‑solid and oral liquid dosage forms. With four stand‑alone production units and strong analytical and developmen…
  • Clinical trial supply & packaging
    …n units and strong analytical and development capabilities, the site supports small‑batch clinical supply through to full‑scale commercial manufacturing. As part of Recipharm’s global CDMO netwo…
  • Analytical testing
    …tand alone facilities supporting development, clinical scale and commercial manufacturing Analytical method development and formulation support GMP area for small batches and clinical trial supply…

Taken from the company's web page for this site. Source: https://www.recipharm.com/about-us/locations/bengaluru, checked 16 Oct 2026. Quoted text shows the wording each tag is based on.

Regulatory timeline

Newest first. Each entry links to the published source. Inspection classifications: NAI = no action indicated, VAI = voluntary action indicated, OAI = official action indicated (FDA definitions). Posted 483 citations are FDA's short summaries, not the full Form 483.

  1. 22 Mar 2024
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 1232473)

  2. 13 Feb 2020
    Form 483 observations 1 posted Form 483 citation(s)

    Citation summaries (1)
    • 21 CFR 211.68(a): Calibration/Inspection/Checking not done

    Source: FDA Data Dashboard – Citations (FEI 3009150119, inspection ID 1119410)

  3. 13 Feb 2020
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 1119410)

  4. 01 Feb 2019
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 1079034)

  5. 11 May 2018
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 1053644)

  6. 19 Mar 2015
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 921695)

  7. 01 Nov 2012
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3009150119, inspection ID 805946)

This is a record of what regulators published, not a rating. Absence of a record here does not mean no record exists; see methodology for what we check and how records are matched.